Table 2.

Pharmacokinetic parameter estimates for the base and final models including the bootstrap (876/1000 runs successful) analysis for the final model

Parameter	Base-model estimate (RSE%)	Final model estimate (RSE%)	Bootstrap median	Bootstrap 95% CI
CL (L/day/70 kg)	0.38 (6)	0.28 (9)	0.28	0.24–0.34
Methylprednisolone	–	1.31 (9)	1.33	1.11–1.59
GBS disability score of 0–2	–	1 (fixed)	1 (fixed)	1 (fixed)
GBS disability score of 3–4	–	1.22 (10)	1.22	0.99–1.49
GBS disability score of 5	–	1.83 (15)	1.85	1.36–2.55
V1 (L)	2.83 (7)	2.87 (7)	2.87	2.54–3.34
Q (L/day)	0.26 (17)	0.25 (17)	0.25	0.16–0.36
V2 (L)	2.85 (11)	2.65 (13)	2.65	2.05–3.39
CBAS (g/L)	15.40 (6)	15.90 (8)	15.81	13.96–17.76
Disease type (if GBS)	0.67 (7)	0.65 (9)	0.66	0.57–0.75

Interindividual variability	Estimate (%RSE) [shrinkage]	Estimate (%RSE) [shrinkage]	Bootstrap median	Bootstrap 95% CI
CL (%)	58.8 (9) [17]	49.9 (10) [19]	49.0%	38.5–61.2
CBAS (%)	23.2 (8) [7]	23.1 (8) [7]	23.0%	19.6–26.8

Residual error	Base model estimate	Final model estimate	Bootstrap median	Bootstrap 95% CI
Proportional	0.12 [20]	0.12 (7) [19]	0.12	0.10–0.13

CBAS baseline immunoglobulin level, CI confidence interval, CL clearance, CV coefficient of variation, GBS Guillain–Barré syndrome, Q intercompartmental clearance, RSE relative standard error, V1 central volume of distribution, V2 peripheral volume of distribution